Severe ileitis associated with capecitabine: Two case reports and review of the literature
- Authors:
- Shing Fung Lee
- Chi Leung Chiang
- Ann Shing Lee
- Frank Chi Shing Wong
- Stewart Yuk Tung
View Affiliations
Affiliations: Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong, SAR, P.R. China
- Published online on: September 2, 2015 https://doi.org/10.3892/mco.2015.635
-
Pages:
1398-1400
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Capecitabine is a commonly used anticancer drug, which has been associated with adverse events, including skin and gastrointestinal symptoms, such as vomiting and diarrhea. We herein present treated two rare cases of capecitabine‑associated ileitis. In one of the patients, ileitis occurred during combination chemotherapy for metastatic colon cancer, despite previous good tolerance to this drug; the other patient developed ileitis following adjuvant single‑agent treatment. The first case is unlike previously reported cases, in which patients had no past exposure to capecitabine. Ileitis may be severe but reversible with early diagnosis and proper supportive treatment, and patients may resume chemotherapy following capecitabine discontinuation.
View References
|
1
|
Saif MW, Katirtzoglou NA and Syrigos KN:
Capecitabine: An overview of the side effects and their management.
Anticancer Drugs. 19:447–464. 2008.PubMed/NCBI
|
|
2
|
Radwan R, Namelo WC, Robinson M, Brewster
AE and Williams GL: Ileitis secondary to oral capecitabine
treatment? Case Rep Med. 154981(2012)2012.
|
|
3
|
Bouma G and Imholz AL: Ileitis following
capecitabine use. Ned Tijdschr Geneeskd. 155:A30642011.([In
Dutch]). PubMed/NCBI
|
|
4
|
Al-Gahmi AM, Kerr IG, Zekri JM and Zagnoon
AA: Capecitabine-induced terminal ileitis. Ann Saudi Med.
32:661–662. 2012.PubMed/NCBI
|
|
5
|
Shoemaker LK, Arora U and Rocha Lima CM:
5-fluorouracil-induced coronary vasospasm. Cancer Contr. 11:46–49.
2004.
|
|
6
|
Jensen SA and Sørensen JB:
5-fluorouracil-based therapy induces endovascular injury having
potential significance to development of clinically overt
cardiotoxicity. Cancer Chemother Pharmacol. 69:57–64. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuzel T, Esparaz B, Green D and Kies M:
Thrombogenicity of intravenous 5-fluorouracil alone or in
combination with cisplatin. Cancer. 65:885–889. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bucaloiu ID, Dubagunta S, Pachipala KK,
Kamal N and Fata F: Small-cell cancers, and an unusual reaction to
chemotherapy: Case 4. Fluorouracil-related small bowel vasculitis.
J Clin Oncol. 21:2442–2443. 2003.PubMed/NCBI
|
|
9
|
Soares PM, Mota JM, Souza EP, Justino PF,
Franco AX, Cunha FQ, Ribeiro RA and Souza MH: Inflammatory
intestinal damage induced by 5-fluorouracil requires IL-4.
Cytokine. 61:46–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Badgwell BD, Camp ER, Feig B, Wolff RA,
Eng C, Ellis LM and Cormier JN: Management of
bevacizumab-associated bowel perforation: A case series and review
of the literature. Ann Oncol. 19:577–582. 2008. View Article : Google Scholar : PubMed/NCBI
|
